Scleral buckling and vitrectomy combination is the most successful in retinal reattachment

Article

A combination of scleral buckling and vitrectomy produced better anatomical success rates and fewer operative procedures in surgery for primary retinal detachment patients.

A combination of scleral buckling and vitrectomy produced better anatomical success rates and fewer operative procedures in surgery for primary retinal detachment patients, according to a study published in Retina.

Dr Schaal Shlomit et al., Department of Ophthalmology and Visual Sciences, University of Louisville, Kentucky, USA, conducted a retrospective interventional comparative case series on 1226 primary retinal detachment patients. The patients were split in to 4 groups: 56 patients underwent pneumatic retinopexy surgery, 316 patients underwent both scleral buckling and vitrectomy surgery, 322 patients underwent scleral buckling surgery and 442 patients had pars plana vitrectomy surgery.

Outcome measures included reattachment success rates, pre- and postoperative visual acuity, complications, and change in refractive error. A 1-year follow-up was completed on all patients.

The results demonstrated an 86% initial success rate for scleral buckling only, 90% for vitrectomy only, 94% for scleral buckling and vitrectomy and 63% for pneumatic retinopexy surgery.

With exception of the pneumatic retinopexy group, there were no statistically significant differences between the other 3 groups. There were also no statistically significant differences in visual acuity between all of the groups.

Overall, the most successful techniques for the repair of primary rhegmatogenous retinal detachments are scleral buckling used in conjunction with vitrectomy, as well as scleral buckling only and vitrectomy only.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.